JP Morgan Chase
FULC icon

JP Morgan Chase’s Fulcrum Therapeutics FULC Stock Holding History

JP Morgan Chase’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$196K Buy
29,792
+9,003
+43% +$83.5K ﹤0.01% 5480
2025
Q4 		$235K Buy
20,789
+2,720
+15% +$27.7K ﹤0.01% 5454
2025
Q3 		$166K Sell
18,069
-8,093
-31% -$58.6K ﹤0.01% 5615
2025
Q2 		$180K Sell
26,162
-183,731
-88% -$983K ﹤0.01% 5291
2025
Q1 		$604K Buy
209,893
+130,773
+165% +$480K ﹤0.01% 4659
2024
Q4 		$372K Sell
79,120
-108,043
-58% -$399K ﹤0.01% 5187
2024
Q3 		$668K Buy
187,163
+154,122
+466% +$1.14M ﹤0.01% 4721
2024
Q2 		$205K Sell
33,041
-125,894
-79% -$954K ﹤0.01% 5157
2024
Q1 		$1.5M Buy
158,935
+147,495
+1,289% +$1.32M ﹤0.01% 4066
2023
Q4 		$77.2K Buy
11,440
+541
+5% +$2.4K ﹤0.01% 5847
2023
Q3 		$48.4K Buy
10,899
+9,585
+729% +$41.9K ﹤0.01% 5817
2023
Q2 		$4.34K Sell
1,314
-188,955
-99% -$555K ﹤0.01% 6199
2023
Q1 		$543K Buy
190,269
+5,583
+3% +$50K ﹤0.01% 4443
2022
Q4 		$1.34M Sell
184,686
-11,274
-6% -$73.5K ﹤0.01% 3858
2022
Q3 		$1.58M Sell
195,960
-2,155
-1% -$15.4K ﹤0.01% 3660
2022
Q2 		$971K Sell
198,115
-2,271
-1% -$22.2K ﹤0.01% 4120
2022
Q1 		$4.74M Sell
200,386
-2,487
-1% -$35.2K ﹤0.01% 3053
2021
Q4 		$3.59M Buy
202,873
+29,146
+17% +$577K ﹤0.01% 3335
2021
Q3 		$4.9M Sell
173,727
-10,845
-6% -$205K ﹤0.01% 3041
2021
Q2 		$1.93M Sell
184,572
-80,933
-30% -$818K ﹤0.01% 3819
2021
Q1 		$3.13M Buy
265,505
+225,705
+567% +$2.79M ﹤0.01% 3364
2020
Q4 		$466K Buy
39,800
+34,465
+646% +$390K ﹤0.01% 4408
2020
Q3 		$41K Buy
5,335
+585
+12% +$7.04K ﹤0.01% 4997
2020
Q2 		$87K Sell
4,750
-16,426
-78% -$259K ﹤0.01% 4625
2020
Q1 		$253K Buy
21,176
+15,264
+258% +$244K ﹤0.01% 4163
2019
Q4 		$99K Buy
5,912
+4,424
+297% +$42.3K ﹤0.01% 4901
2019
Q3 		$10K Buy
+1,488
New +$16.5K ﹤0.01% 5499

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

JP Morgan Chase's FULC Position: Q1 2026 in Review

JP Morgan Chase increased its Fulcrum Therapeutics (FULC) stake by 43% in Q1 2026, buying an estimated $83.5K and bringing the position to 29,792 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #5480.

JP Morgan Chase first reported a position in FULC in Q3 2019 and has held it in 27 quarters since. The position peaked at $4.9M in Q3 2021. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • JP Morgan Chase held 29,792 shares of Fulcrum Therapeutics worth $196K as of Q1 2026.
  • JP Morgan Chase bought 9,003 Fulcrum Therapeutics shares in Q1 2026, an estimated $83.5K.
  • Fulcrum Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5480 holding.
  • JP Morgan Chase first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • JP Morgan Chase's Fulcrum Therapeutics position peaked at $4.9M in Q3 2021.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.